These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2463445)

  • 1. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
    Nicholson S; Sainsbury JR; Halcrow P; Chambers P; Farndon JR; Harris AL
    Lancet; 1989 Jan; 1(8631):182-5. PubMed ID: 2463445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
    Harris AL; Nicholson S; Sainsbury JR; Farndon J; Wright C
    J Steroid Biochem; 1989; 34(1-6):123-31. PubMed ID: 2576295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
    Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
    Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
    Nicholson S; Halcrow P; Sainsbury JR; Angus B; Chambers P; Farndon JR; Harris AL
    Br J Cancer; 1988 Dec; 58(6):810-4. PubMed ID: 3224082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
    Sainsbury JR; Farndon JR; Needham GK; Malcolm AJ; Harris AL
    Lancet; 1987 Jun; 1(8547):1398-402. PubMed ID: 2884496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
    Holdaway IM
    Aust N Z J Surg; 1981 Aug; 51(4):345-7. PubMed ID: 6944051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. St. Gallen endocrine response classes predict recurrence rates over time.
    Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
    Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
    Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
    Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
    Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.
    Nicholson S; Richard J; Sainsbury C; Halcrow P; Kelly P; Angus B; Wright C; Henry J; Farndon JR; Harris AL
    Br J Cancer; 1991 Jan; 63(1):146-50. PubMed ID: 1846551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of epidermal growth factor receptor in breast carcinoma.
    Lewis S; Locker A; Todd JH; Bell JA; Nicholson R; Elston CW; Blamey RW; Ellis IO
    J Clin Pathol; 1990 May; 43(5):385-9. PubMed ID: 2370306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
    Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
    Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
    J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.